204 related articles for article (PubMed ID: 36452303)
1. Unraveling the impact of
Zhou Z; Qiu Y; Li K; Sun Q; Xie M; Huang P; Yu Y; Wang B; Xue J; Zhu Z; Feng Z; Zhao J; Wu P
Front Cell Infect Microbiol; 2022; 12():1030315. PubMed ID: 36452303
[TBL] [Abstract][Full Text] [Related]
2. Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study.
Li K; Chen C; Zeng J; Wen Y; Chen W; Zhao J; Wu P
BMC Urol; 2022 Mar; 22(1):39. PubMed ID: 35305613
[TBL] [Abstract][Full Text] [Related]
3. Urinary Microbiome and Psychological Factors in Women with Overactive Bladder.
Wu P; Chen Y; Zhao J; Zhang G; Chen J; Wang J; Zhang H
Front Cell Infect Microbiol; 2017; 7():488. PubMed ID: 29230385
[No Abstract] [Full Text] [Related]
4. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
6. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
Cho SY; Jeong SJ; Lee S; Kim J; Lee SH; Choo MS; Oh SJ
Neurourol Urodyn; 2021 Jan; 40(1):286-294. PubMed ID: 33389776
[TBL] [Abstract][Full Text] [Related]
7. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
Chen SF; Kuo HC
Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
[TBL] [Abstract][Full Text] [Related]
9. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
[TBL] [Abstract][Full Text] [Related]
10. Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
Kakizaki H; Lee KS; Katou D; Yamamoto O; Sumarsono B; Uno S; Yamaguchi O
Adv Ther; 2021 Jan; 38(1):739-757. PubMed ID: 33245533
[TBL] [Abstract][Full Text] [Related]
11. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
[TBL] [Abstract][Full Text] [Related]
13. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
[TBL] [Abstract][Full Text] [Related]
14. Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms.
Thomas-White K; Taege S; Limeira R; Brincat C; Joyce C; Hilt EE; Mac-Daniel L; Radek KA; Brubaker L; Mueller ER; Wolfe AJ
Am J Obstet Gynecol; 2020 Nov; 223(5):727.e1-727.e11. PubMed ID: 32791124
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Low Urin Tract Symptoms; 2019 Apr; 11(2):O65-O70. PubMed ID: 29473309
[TBL] [Abstract][Full Text] [Related]
16. Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
Wang CC; Jiang YH; Kuo HC
Low Urin Tract Symptoms; 2019 Apr; 11(2):O180-O185. PubMed ID: 30565417
[TBL] [Abstract][Full Text] [Related]
17. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
[TBL] [Abstract][Full Text] [Related]
18. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
[TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
Inoue M; Yokoyama T
Acta Med Okayama; 2019 Oct; 73(5):387-392. PubMed ID: 31649364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
